Press release - 21/02/2018 German Cancer Award for Michael Baumann Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research". The science award, which is sponsored by the German Cancer Society and the German Cancer Foundation, is one of the most prestigious distinctions in cancer medicine in Germany.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/german-cancer-award-for-michael-baumann
Dossier - 10/03/2014 Cancer therapy and cancer diagnostics Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation. The early detection and classification of tumours is crucial for the successful treatment of the disease, and molecular…https:////www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
Article - 26/01/2017 Clinical cancer registration to improve patient treatment and care Germany records around 500,000 new cases of cancer every year. The number is steadily growing, mainly due to an ageing population that leads to an increased risk of cancer. The German government is planning to establish clinical cancer registries in all German states so that all cancer patients receive the best possible treatment. In Baden-Württemberg, all new cancer cases are already recorded. However, the data are still not as comprehensive as…https:////www.gesundheitsindustrie-bw.de/en/article/news/clinical-cancer-registration-to-improve-patient-treatment-and-care
Vision Zero in oncology - 02/09/2019 Call for a comprehensive master plan for preventing and treating cancer While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.https:////www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
Press release - 02/06/2010 immatics enters Collaboration with the National Cancer Institute (NCI) immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-enters-collaboration-with-the-national-cancer-institute-nci
Press release - 12/10/2011 Autoimmune Diseases Affect Cancer Risk In a recently published study, scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have calculated the interrelations between autoimmune diseases and cancer of the digestive tract. They discovered that many autoimmune diseases increase the cancer risk, while others, such as rheumatism, are associated with a significantly lower bowel cancer risk. These differing impacts on cancer risk may be attributable to the…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/autoimmune-diseases-affect-cancer-risk
Press release - 26/05/2014 50 years of research for life without cancer The German Cancer Research Center (DKFZ) in Heidelberg turns 50 this year. Conducting research on the basic biological mechanisms of cancer, the DKFZ has been instrumental in our current understanding of the development and growth of cancer and has advanced the development of enhanced methods for the prevention, diagnosis and treatment of cancer. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/50-years-of-research-for-life-without-cancer
Press release - 04/02/2010 World Cancer Day: encouraging the prevention, detection and treatment of cancer World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
Article - 09/03/2015 Treating cancer by activating the immune system Vaccines that prevent infection with cancer-causing viruses are already available. Moreover, the development of therapeutic vaccines for the treatment of a number of other cancers is well under way. These vaccines not only prevent the development of cancer, but also treat early stages of cancer. Antigen-armed antibodies have long been used in vaccines against infectious diseases, and can now also be used for treating cancer. https:////www.gesundheitsindustrie-bw.de/en/article/news/treating-cancer-by-activating-the-immune-system
Dossier - 05/11/2012 Cancer – basic research, successes and trends Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer. This…https:////www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends
Press release - 09/03/2011 DKFZ and IBM have signed a collaboration agreement on cancer genome analysis The International Cancer Genome Project analyzes the complete genomes of thousands of cancer patients. This generates enormous amounts of data. To find those gene segments which are pivotal for cancer development and treatment, intelligent IT systems are needed. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg and IBM have signed a strategic partnering agreement at CeBIT 2011. The aim of the agreement is to…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-ibm-have-signed-a-collaboration-agreement-on-cancer-genome-analysis
Press release - 06/10/2008 Harald zur Hausen wins Nobel Prize in Medicine Harald zur Hausen the long-time chairman and scientific director of the German Cancer Research Centre DKFZ a member of the Helmholtz Society discovered that human papillomaviruses HPV lead to cervical cancer. His discovery led to the development of a vaccine for cervical cancer which is the third most frequent type of cancer in women.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/harald-zur-hausen-wins-nobel-prize-in-medicine
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Press release - 27/10/2010 Cancer Research and Cancer Medicine at Top Level German Research Minister Schavan and Baden-Wuerttembergs Prime Minister Mappus have inaugurated DKFZs renovated main building and visited NCTs new building. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-research-and-cancer-medicine-at-top-level
Press release - 05/06/2010 No rest for cancer cells A research team led by scientists from the German Cancer Research Centre worked out that cancer cells rely on the tension of specific protein fibres to be able to multiply. Proteins that maintain this tension have now become promising targets for new target-specific anticancer drugs If these proteins are switched off cancer cells die.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/no-rest-for-cancer-cells
Press release - 26/11/2020 New mechanism of action: A small-molecule degrades a cancer-promoting protein by gluing it into filaments “Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting proteins directly to the molecular machinery of a cell’s disposal system, leading to the subsequent degradation of the cancer-driving proteins and anti-tumor activity. Scientists from Heidelberg and USA have now deciphered another mechanism whereby a small molecule can degrade a cancer protein. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-mechanism-action-small-molecule-degrades-cancer-promoting-protein-gluing-it-filaments
Article - 11/12/2017 KDM4 – an efficient target for the therapy of triple-negative breast cancer While breast cancer survival has clearly improved in recent years, women with triple-negative breast cancer have benefitted very little from progress in cancer medicine. Targeted therapies aimed at inhibiting epigenetic regulators might offer a potential new option for the treatment of breast cancer. Prof. Dr. Roland Schüle and Dr. Jochen Maurer have discovered an epigenetic enzyme called KDM4 and come up with a new cell model that significantly…https:////www.gesundheitsindustrie-bw.de/en/article/news/kdm4-an-efficient-target-for-the-therapy-of-triple-negative-breast-cancer
Press release - 26/01/2011 Uncovering the Genetics of Prostate Cancer Germany will contribute another project to the International Cancer Genome Consortium ICGC. Coordinated by the German Cancer Research Center and the University Medical Center Hamburg-Eppendorf physicians and molecular biologists will now start to investigate the genetic causes of early prostate cancer. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/uncovering-the-genetics-of-prostate-cancer-1
Cancer immunotherapy - 06/09/2018 The immunogenicity of tumours and the development of new cancer medicines Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.https:////www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
Article - 25/03/2013 Epigenetics for personalised cancer care for women Every year in the EU, 45,300 women are diagnosed with ovarian cancer and 330,000 with breast cancer. Ovarian cancer has a mortality rate of around 64% and breast cancer around 27%*. The EU-funded research project EpiFemCare aims at improving cancer detection and subsequent patient care. The research project aims to develop blood tests based on epigenetic DNA modifications, i.e. the methylation of the base cytosine, for the identification of…https:////www.gesundheitsindustrie-bw.de/en/article/news/epigenetics-for-personalised-cancer-care-for-women
Press release - 14/01/2008 Prostate cancer: Improving the success of treatment Prostate cancer is the most frequent malignant tumour in men. Researchers from Freiburg and Bonn have succeeded in developing the basics for new therapies in particular for the treatment of advanced prostate cancer. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-improving-the-success-of-treatment
Press release - 14/01/2010 First Population-wide Evidence: Colonoscopy Protects From Cancer Persons who have had a colonoscopy in the past ten years are much less likely to be diagnosed with advanced precancerous stages of bowel cancer. Particularly on the left side of the colon, the risk for cancer and precancerous stages is dramatically reduced, as scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have found out. Their results underline the great potential of colonoscopy for preventing bowel…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/first-population-wide-evidence-colonoscopy-protects-from-cancer
Article - 04/02/2013 DKFZ-HIPO – the Heidelberg Center for Personalised Oncology The German Cancer Research Center (DKFZ) and the National Center for Tumour Diseases (NCT) have jointly initiated the Heidelberg Center for Personalised Oncology (HIPO) which provides cancer patients with high-throughput genetic and molecular analyses. In anticipation of the upcoming World Cancer Day on 4th February 2013, the potential of high-throughput genetic and molecular analyses in improving cancer therapy was presented at a workshop held…https:////www.gesundheitsindustrie-bw.de/en/article/news/dkfz-hipo-the-heidelberg-center-for-personalised-oncology
Article - 11/05/2015 Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease Lung cancer is one of the most common malignant diseases and one of the leading causes of cancer-related deaths worldwide. 90% of all lung cancer cases in men and 80% in women are due to long-term exposure to tobacco smoke. In Germany, around 140 new cases are diagnosed every day, and 50,000 people die of lung cancer every year. PD Dr. Gian Kayser, senior consultant in the Department of Clinical Pathology at Freiburg University Medical Centre,…https:////www.gesundheitsindustrie-bw.de/en/article/news/lung-cancer-mtss1-is-a-putative-marker-of-tumour-progression-and-metastatic-disease
Press release - 24/08/2012 Cancer Survival in Germany after the fall of the Iron Curtain Two decades after the fall of the Wall, cancer survival rates in East and West Germany have become almost equal. This is reported in a recent study by a team of epidemiologists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and eleven German cancer registries. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-survival-in-germany-after-the-fall-of-the-iron-curtain